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ABSTRACT
Platinum-derived drugs such as cisplatin and carboplatin are among the most 
commonly used cancer chemotherapy drugs, but very few specific molecular and 
cellular markers predicting differential sensitivity to these agents in a given tumor 
type have been clearly identified. Epigenetic gene silencing is increasingly being 
recognized as a factor conferring distinct tumoral drug sensitivity, so we have used 
a comprehensive DNA methylation microarray platform to interrogate the widely 
characterized NCI60 panel of human cancer cell lines with respect to CpG methylation 
status and cisplatin/carboplatin sensitivity. Using this approach, we have found 
promoter CpG island hypermethylation-associated silencing of the putative DNA/
RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to 
platinum compounds. We have also experimentally validated these findings in vitro. 
In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also 
known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for 
the observed chemoresistance effect. Most importantly, we have been able to extend 
these findings clinically, following the observation that those patients with ovarian 
and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response 
to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 
epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.
INTRODUCTION
Platinum-derived compounds, such as cisplatin 
and its second-generation analogue carboplatin, are drugs 
widely used to treat human malignancies [1]. Either alone 
or in combination with other antitumor drugs, they have 
shown to be useful treatments against a broad range of 
solid cancers, including testicular, ovarian, head and neck, 
colorectal, bladder and lung cancers [2]. In some cases, 
such as in testicular cancer, they have even changed the 
natural history of the disease [3]. Unfortunately, these 
drugs have several side effects, such as renal impairment, 
neurotoxicity and ototoxicity, which affect strongly the 
quality of life of the patients [1, 4]. This fact highlights the 
importance of discovering biological or cellular markers to 
predict, within a given tumor, whether a patient’s disease 
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will be sensitive or resistant to their antiproliferative 
effect. However, despite the ubiquity of these agents, 
we still lack of good biomarkers of platinum agents 
response that allow us to avoid unnecessary side effects 
on patients with a resistant malignance. Resistance to 
platinum agents can be due to several mechanisms [5]. 
The major cytotoxic mode of action of this kind of drugs 
is mediated by their interaction with DNA to form DNA 
adducts which disrupt the structure of the DNA molecule 
[1]. This alteration of the DNA leads to the activation of 
DNA damage recognition and repair systems in order 
to allow cell cycle progression. If the damage cannot be 
repaired, cell death will be induced through the increase of 
apoptotic signals [6]. Related to this, resistance to platinum 
agents can emerge by increasing DNA repair activity or 
by attenuating DNA damage-mediated apoptotic signals. 
Thus, one aspect that has recently been garnering interest 
is the existence of different “repertoires” of DNA repair 
defects in each patient [7]. In this context, attention has 
been drawn to BRCA1 for which, in addition to its genetic 
alterations, the epigenetic inactivation of its expression had 
been associated to an enhanced platinum response in breast 
and ovarian tumors [8–10]. Epigenetic inactivation of gene 
expression by CpG promoter island hypermethylation is 
a common event in cancer cells [11]. The utility of CpG 
promoter island hypermethylation events as biomarkers for 
cancer progression or drugs response have already been 
demonstrated in several studies [12, 13, 14]. Following 
this lead, and as reported here, we have adopted a non-
biased global genomic approach to identify cancer-specific 
epigenetic changes that could predict chemosensitivity to 
platinum-based compounds.
RESULTS
DNA methylation analysis of NCI60 cell line 
panel identifies SLFN11 CpG promoter island 
hypermethylation as candidate biomarker of 
cisplatin and carboplatin resistance
To achieve our particular goal, we have interrogated 
a comprehensive DNA methylation microarray platform 
[15] for the NCI60 cancer cell line panel in relation to 
their validated cisplatin and carboplatin sensitivity data 
[16, 17]. Overall, we analyzed 482,422 CpGs in the 
60 cancer cell lines of the NCI60 panel (Figure 1A). The 
complete DNA methylation data are freely available from 
the GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc 
.cgi?token=srydsegkptafnwj&acc=GSE66872) and 
NCI60 websites. In order to identify strong candidate 
genes with differential methylation respect to their 
cisplatin or carboplatin sensitivity, we imposed 
stringent criteria and only considered those CpG sites 
harbored in CpG islands located within ± 1,500 bp of 
the transcription start site of the corresponding gene. 
These CpG sites were then analyzed along the NCI60 
panel by examining the Pearson’s correlation coefficients 
between their methylation values and the cisplatin and 
carboplatin IC50 values obtained from the Developmental 
Therapeutics Program of the NCI (http://dtp.nci.nih 
.gov/). Through this analysis we obtained a total of 33 
CpG sites which methylation correlated significantly for 
both cisplatin and carboplatin IC50 values (Table 1). Most 
importantly, we found the highest correlation between 
methylation and cisplatin and carboplatin resistance in 
several CpG sites located in the CpG promoter island 
of Schlafen-11 (SLFN11). The correlation between 
high SLFN methylation levels and increased resistance 
to cisplatin and carboplatin was maintained even if we 
excluded colorectal (all methylated) and leukemia/
CNS (mostly unmethylated) cell lines (Supplementary 
Figure S1). Given these results, we decided to study the 
methylation status of the whole CpG promoter island of 
SLFN11 and its relation with cisplatin and carboplatin 
IC50 values. SLFN11 presents a CpG island located around 
its transcription start site what makes it a candidate gene 
for hypermethylation-associated inactivation in human 
cancer (Figure 1B). The DNA methylation microarray 
approach in the NCI60 panel of cancer cell lines revealed 
SLFN11 methylation (higher than 0.5) in 25% (15 of 59) 
of cell lines, whereas for the remaining 75% (44 of 59) of 
cell lines the 5′-end CpG island remained unmethylated 
(lower than 0.5) (Figure 1B). All normal tissues analyzed 
in our cohort (n = 64), counterparts of the NCI60 cancer 
types, were found to be unmethylated at the SLFN11 CpG 
island.
The classification of cell lines from NCI60 
based on the average methylation value of all CpG 
sites in SLFN11 CpG promoter island, corroborated 
the previously obtained association between increased 
chemoresistance to cisplatin and carboplatin (Figure 
1C). Thus, SLFN11 promoter methylated cell lines group 
showed cisplatin and carboplatin IC50 average values 
significantly higher than the SLFN11 unmethylated cell 
lines group. In addition, by using the available data of 
SLFN11 gene expression [18], we found a significant 
association between SLFN11 CpG island methylation 
with diminished SLFN11 RNA levels (Figure 1D). 
In this regard, the expression levels of SLFN11 
correlate with cisplatin and carboplatin drug sensitivity 
(18) and we have confirmed these data running the 
CellMiner Analysis Tool (http://discovery.nci.nih.gov/
cellminer/) (Supplementary Figure S2). Importantly, 
using a tridimentional dot-plot distribution, we found a 
significant common correlation in the NCI-60 cell lines 
between the three parameters: IC50 values for sensitivity 
to platinum drugs, SLFN11 expression and SLFN11 
promoter methylation (Supplementary Figure S2). Thus, 
the candidate DNA methylation-associated silencing of 
SLFN11 as a predictor of chemoresistance to platinum 
agents in cancer became our main focus of interest.
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Hypermethylation of SLFN11 CpG promoter 
island is associated with a inactivation of 
SLFN11 gene expression in cancer cells
Having observed the mentioned SLFN11 promoter 
CpG island hypermethylation profiles, we assessed 
in greater detail their association with the putative 
transcriptional inactivation of the SLFN11 gene at the RNA 
and protein levels. To this end, we first performed bisulfite 
genomic sequencing of multiple clones in eight selected 
cancer cell lines from different tissue types with different 
cisplatin and carboplatin sensitivities that confirmed the 
DNA methylation patterns obtained by the microarray 
approach (Figure 2A). The cancer cell lines HCT-116, HCT-
15, MDA-MB-231, and MCF7, hypermethylated at the 
SLFN11 CpG island, had minimal expression of the SLFN11 
RNA transcript, as determined by quantitative reverse 
transcription-PCR (Figure 2B), and protein, as assessed 
by western blot (Figure 2B) and immunofluorescence 
(Figure 2C). By contrast, cancer cell lines unmethylated 
at the SLFN11 promoter (U251, NCI-H23, DU145 and 
SK-OV-3) expressed highly detectable SLFN11 RNA 
transcript (Figure 2B) and protein levels (Figure 2B and 
Figure 2C). We established a further link between SLFN11 
CpG island hypermethylation and its gene silencing by 
treating the HCT-15 and MDA-MB-231 cell lines with a 
DNA-demethylating agent. Treatment of these SLFN11 
methylated cell lines with 5-aza-2-deoxycytidine restored 
SLFN11 expression at the RNA and protein levels (Figure 
2D). These results were confirmed in the isogenic HCT-116 
cell line, in which the two major DNA methyltransferases, 
DNMT1 and DNMT3B, had been genetically disrupted 
(DKO) [19]. We observed that the SLFN11 CpG island was 
unmethylated in double knockout (DKO) cells and, most 
Figure 1: Determination of cisplatin and carboplatin sensitivity in the NCI60 panel of human cancer cell lines with 
respect to promoter CpG island methylation, analyzed by the 450K DNA methylation microarray. A. Distribution of 
promoter CpG island methylation in the NCI60 panel and IC50 values for cisplatin and carboplatin (-log [M]). The 33 CpG sites significant 
for both cisplatin and carboplatin sensitivity are shown. Red, methylated CpG; green, unmethylated CpG. B. DNA methylation profile 
of the CpG island promoter for the SLFN11 gene with respect to DNA methylation microarray values in the NCI60 panel. Single CpG 
absolute methylation levels (0 – 1) are shown. Red, methylated; green, unmethylated. C. Box and whisker plots demonstrating that SLFN11 
promoter CpG island hypermethylation is significantly associated with decreased sensitivity to cisplatin and carboplatin in the NCI60 panel. 
***p < 0.001: ****p < 0.0001, Student’s t test. (C) Box and whisker plots demonstrating SLFN11 promoter CpG island hypermethylation 
is significantly associated with decreased SLFN11 RNA levels in the NCI60 panel. ****p < 0.0001, Student’s t test.
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Table 1: Common candidate CpGs for Cisplatin and Carboplatin
TargetID CHR MAPINFO UCSC_REFGENE_NAME UCSC_REFGENE_GROUP Pearson Cisplatin
Pval 
Cisplatin
Pearson 
Carboplatin
Pval 
Carboplatin
cg01348733 17 33700757 SLFN11;SLFN11;SLFN11; SLFN11;SLFN11
TSS200;TSS200; 
TSS200;TSS200; 
TSS200
0.61 1.66E-07 0.55 5.55E-06
cg18608369 17 33700759 SLFN11;SLFN11;SLFN11; SLFN11;SLFN11
TSS200;TSS200; 
TSS200;TSS200; 
TSS200
0.61 2.41E-07 0.55 4.36E-06
cg14380270 17 33700747 SLFN11;SLFN11;SLFN11; SLFN11;SLFN11
TSS200;TSS200; 
TSS200;TSS200; 
TSS200
0.59 7.52E-07 0.52 2.06E-05
cg18108623 17 33701321 SLFN11;SLFN11;SLFN11; SLFN11;SLFN11
TSS1500;TSS1500; 
TSS1500;TSS1500; 
TSS1500
0.59 4.96E-07 0.52 1.97E-05
cg26573518 17 33700745 SLFN11;SLFN11;SLFN11; SLFN11;SLFN11
TSS200;TSS200; 
TSS200;TSS200; 
TSS200
0.58 1.03E-06 0.52 2.33E-05
cg26560414 16 66638433 CMTM3;CMTM3;CMTM3; CMTM3;CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;TSS200 0.56 3.11E-06 0.56 3.68E-06
cg00355909 16 66638320
CMTM3;CMTM3;CMTM3; 
CMTM3; 
CMTM3;CMTM3;CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;1stExon; 
1stExon;TSS1500
0.56 2.54E-06 0.54 8.67E-06
cg03668718 17 33701350 SLFN11;SLFN11;SLFN11; SLFN11;SLFN11
TSS1500;TSS1500; 
TSS1500;TSS1500; 
TSS1500
0.56 3.23E-06 0.49 7.12E-05
cg08682544 16 66638438 CMTM3;CMTM3;CMTM3; CMTM3;CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;TSS200 0.55 5.01E-06 0.53 1.10E-05
cg21956337 15 88799707 NTRK3;NTRK3;NTRK3 TSS200;TSS200;TSS200 0.54 9.46E-06 0.57 1.68E-06
cg09233013 16 66638412 CMTM3;CMTM3;CMTM3; CMTM3;CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;TSS200 0.53 1.57E-05 0.53 1.51E-05
cg13969265 8 140716673 KCNK9 TSS1500 0.53 1.13E-05 0.52 1.73E-05
cg14081924 3 142682378 PAQR9 TSS1500 0.53 1.26E-05 0.51 2.73E-05
cg06445928 16 66638407 CMTM3;CMTM3;CMTM3; CMTM3;CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;TSS200 0.52 2.31E-05 0.52 1.93E-05
cg27406373 3 142682291 PAQR9 TSS200 0.52 1.95E-05 0.50 4.62E-05
cg15852572 3 142682288 PAQR9 TSS200 0.52 1.95E-05 0.49 5.95E-05
cg26584528 11 64512032 RASGRP2;RASGRP2; RASGRP2 TSS1500;5′UTR;5′UTR 0.52 1.97E-05 0.49 5.85E-05
cg12665504 5 100239050 ST8SIA4;ST8SIA4 TSS200;TSS200 0.51 2.95E-05 0.56 2.78E-06
cg04380513 5 100238983 ST8SIA4;ST8SIA4;ST8SIA4 TSS200;1stExon;5′UTR 0.51 3.30E-05 0.54 6.54E-06
cg05330297 14 90527606 KCNK13 TSS1500 0.51 2.94E-05 0.54 7.47E-06
cg03975797 5 100238977 ST8SIA4;ST8SIA4;ST8SIA4 TSS200;1stExon;5′UTR 0.51 3.60E-05 0.52 2.22E-05
cg16785690 9 135037323 NTNG2 TSS200 0.50 5.45E-05 0.55 5.15E-06
cg08452658 15 83776271 TM6SF1;TM6SF1 TSS200;TSS200 0.50 3.79E-05 0.51 3.34E-05
cg08601917 16 66638396 CMTM3;CMTM3;CMTM3; CMTM3;CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;TSS200 0.50 5.11E-05 0.51 2.73E-05
cg01717150 8 140716495 KCNK9 TSS1500 0.50 4.58E-05 0.49 6.87E-05
(Continued)
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TargetID CHR MAPINFO UCSC_REFGENE_NAME UCSC_REFGENE_GROUP Pearson Cisplatin
Pval 
Cisplatin
Pearson 
Carboplatin
Pval 
Carboplatin
cg18417423 6 80657436 ELOVL4 TSS200 0.50 5.10E-05 0.48 8.51E-05
cg23297477 16 66638293
CMTM3;CMTM3; 
CMTM3;CMTM3; 
CMTM3;CMTM3; 
CMTM3
5′UTR;5′UTR;5′UTR; 
1stExon;1stExon; 
1stExon;TSS1500
0.49 5.72E-05 0.60 4.84E-07
cg05258261 3 140770608 SPSB4 TSS200 0.49 7.85E-05 0.56 3.66E-06
cg27515369 3 140770599 SPSB4 TSS200 0.49 6.33E-05 0.55 3.98E-06
cg23332582 3 140770308 SPSB4 TSS1500 0.49 6.39E-05 0.52 1.58E-05
cg20078466 7 50344331 IKZF1 TSS200 0.49 8.02E-05 0.50 5.30E-05
cg16673106 5 100239071 ST8SIA4;ST8SIA4 TSS200;TSS200 0.48 8.83E-05 0.54 6.88E-06
cg01513081 6 105584780 BVES;BVES TSS1500;TSS1500 0.48 8.78E-05 0.48 9.07E-05
Pearson correlation coefficient and p value are shown for the methylation value of each CpG respect Cisplatin and Carboplatin IC50 values along NCI60 
panel.
importantly, that SLFN11 transcription was restored as 
showed the quantitative reverse transcription-PCR assay 
(Figure 2E). Western blot analysis confirmed the absence 
of SLFN11 protein expression in HCT-116 cells and its 
recovery in DKO cells (Figure 2E). Importantly, we found 
that pre-treatment of the SLFN11 hypermethylated cell 
line MDA-MB-231 with the inhibitor of DNA methylation 
5-azacytidine followed by the addition of cisplatin or 
carboplatin increased the sensitivity to these compounds 
(Supplementary Figure S3). In a similar manner, DKO 
cells (undergoing the described demethylation-associated 
reactivation of SLFN11) were also more sensitive to 
cisplatin or carboplatin than the parental HCT-116 cell line 
(Supplementary Figure S3).
In vitro silencing of SLFN11 gene expression 
increases resistance to cisplatin and carboplatin 
treatments
Having shown the epigenetic silencing of SLFN11 
gene expression by DNA methylation of its CpG promoter 
island, we next sought to demonstrate that this SLFN11 
epigenetic inactivation functionally contributed to platinum 
resistance. With that end, we decided to downregulate the 
expression of SLFN11 by the short hairpin RNA approach 
in SLFN11-expressing and unmethylated SK-OV-3 and 
NCI-H23 cells. These cell lines represent two tumor types 
commonly treated with platinum-based chemotherapy, 
ovarian and lung cancer, respectively. Two Sh- sequences 
targeting different regions of SLFN11 RNA transcript were 
use to assess the relation between SLFN11 silencing and 
platinum resistance. For both shRNA against SLFN11 a 
notable reduction on SLFN11 protein levels was observed 
compare to shRNA-scramble cells (Figure 3A). IC50 values 
to cisplatin and carboplatin treatment were then determined 
for all constructions by MTT assay. Under this shRNA-
mediated downregulation of SLFN11 both cell lines showed 
statistically significantly increased IC50 values for platinum 
treatments than the shRNA-scramble cells (Figure 3B). 
Conversely, upon efficient recovery of SLFN11 expression 
by transfection of the full-length SLFN11 protein in the 
hypermethylated and silenced HCT-15 and MCF7 cancer 
cell lines, we observed a significant increase in the sensitivity 
to cisplatin and carboplatin (Supplementary Figure S4).
SLFN11 co-immunoprecipites with the BRCA1-
interactor DHX9
Although some data have been reported about 
the putative function of SLFN11 related with immune 
system response [20], very little is known about the 
role of SLFN11 in other contexts such as cell response 
to platinum-induced DNA damage. To gain further 
knowledge of SLFN11 activity, we searched for protein 
partners of SLFN11 by combining immunoprecipitation 
and mass spectrometry (MS). We compared SLFN11 
immunoprecipitates obtained from NCI-H23 cells (SLFN11 
unmethylated and expressing the gene) to SLFN11 
shRNA-mediated donwregulation and in shRNA-scramble 
cells (Figure 3A). We observed in the gel lanes of the 
SLFN11 downregulated shRNA cells’ immunoprecipitates 
that a particular band was significantly diminished relative 
to the shRNA-scramble cells (Figure 3C). This band 
was isolated for further characterization by MS. Mass 
spectrometry (MS) analysis identified the isolated band 
as the protein DEAH (Asp-Glu-Ala-His) box helicase 
9 (DHX9) with a Mascot Protein score of 83.9, thought 
the identification of two peptides: DINTDFLLVVLR 
(score 56.4) and GMTLVTPLQLLLFASK (score 61.4) 
(Figure 3D). DHX9 is also known as RNA helicase A 
(RHA) which has been related to DNA damage repair 
and stability, and characterized as interactor of BRCA1 
in this context [21, 22, 23]. Direct binding of SLFN11 
to DHX9 was confirmed by co-immunoprecipitation 
and western-blot using specific antibodies against 
DHX9 and SLFN11 in NCI-H23, DU145 and U251 
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cells (Figure 3E and Supplementary Figure S5). We also 
performed immunefluorescence assays in NCI-H23 cells 
demonstrating at least partial colocalization of the SLFN11 
and DHX9 proteins in the cell nucleus (Figure 3F).
SLFN11 CpG promoter island hypermethylation 
correlates with worse overcome in ovarian or 
lung cancer patients undergoing treatment with 
platinum-derived drugs
Finally, given our in vitro findings that cancer cells 
with SLFN11 methylation-associated silencing are resistant 
to cisplatin and carboplatin, we wondered whether the same 
effect could be observed in clinical samples. To address 
this question, we studied two cohorts of patients with 
primary ovarian and non-small cell lung tumors, both of 
which are human malignancies in which platinum-derived 
treatments are commonly used [1, 2]. The study of a first 
clinical cohort of 41 cases of papillary serous ovarian 
cancer (Table 2), all of whom were treated with cisplatin or 
carboplatin, showed SLFN11 methylation in 39% (n = 16 of 
41) of the patients analyzed by methylation-specific PCR. 
Importantly, we observed that SLFN11 hypermethylation 
was significantly associated with shorter overall survival 
(OS) (log-rank test, P = 0.006; HR = 3.45; 95% confidence 
interval [CI] = 1.35 – 8.80) (Figure 4A). For the 40 patients 
for whom progression-free survival (PFS) information was 
available, SLFN11 hypermethylation was also significantly 
associated with shorter PFS (log-rank test, P = 0.003; 
HR = 2.99; 95% CI = 1.40 – 6.40) (Figure 4A). According 
to the Cox regression multivariate test, SLFN11 was an 
independent prognostic factor of OS (log-rank test, P = 0.02; 
Figure 2: DNA methylation-associated transcriptional silencing of SLFN11. A. Bisulfite genomic sequencing of SLFN11 
promoter CpG island. CpG dinucleotides are represented as short vertical lines. At least eight single clones are shown for each sample. 
Presence of a methylated or unmethylated cytosine is indicated by a red or green square, respectively. MDA-MB-231, MCF-7, HCT-15, and 
HCT-116 show dense CpG island methylation. B. Expression levels of the SLFN11 transcript and protein determined by real-time reverse 
transcription-PCR and western blot, respectively. C. SLFN11 (green label) and DAPI (blue label) immunofluorescence in the studied cancer 
cell lines. D. The expression of SLFN11 RNA transcript and protein was restored in the methylated HCT15 and MDA-MB-231 cells by 
treatment with the demethylating drug 5-aza-2-deoxycytidine (AZA). E. Genetic disruption of the two major DNA methyltransferases 
DNMT1 and DNMT3B (in DKO cells) also restored SLFN11 RNA and protein expression in HCT-116 cells. Data are summarized as the 
mean ± s.e.m. of three biological replicates. ***p < 0.001,
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HR = 2.91; 95% CI = 1.14 – 7.41) and PFS (log-rank test, 
P = 0.005; HR = 3.35; 95% CI = 1.75 – 6.42) prognostic 
factor (Figure 4B). A similar pattern was observed when 
we studied a clinical cohort of non-small cell lung cancer 
adenocarcinomas (n  = 22) who received platinum-
based chemotherapy (Table 3). The presence of SLFN11 
hypermethylation, detected by the DNA methylation 
microarray method, was found in 13.6% (n = 3 of 22) of the 
cases. Although OS information was not available for these 
patients, we found that SLFN11 CpG island hypermethylation 
was significantly associated with shorter PFS (log-rank test, 
P = 0.031; HR = 4.05; 95% CI = 1.03 – 16.01) (Figure 4C). 
The Cox multivariate regression model showed that SLFN11 
also was an independent prognostic factor of PFS (log-rank 
test, P = 0.02; HR = 5.75; 95% CI = 1.37 – 24.2) (Figure 4D). 
Thus, the clinical results resemble those derived from the 
aforementioned cell cultures, which suggest increased 
chemoresistance of SLFN11 hypermethylated tumors to 
platinum-derived treatments.
DISCUSSION
Herein, we have analyzed the DNA methylome of 
the well characterized cancer cell line panel NCI60 by 
Figure 3: Impact of SLFN11 in cisplatin/carboplatin chemoresistance in vitro and the search for a protein 
partner. A. Western blot showing the in vitro depletion by the short hairpin RNA approach in SK-OV-3 (ovarian) and NCI-H23 (lung) 
cancer cell lines of the SLFN11 protein. B. Cell viability determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay following exposure to cisplatin and carboplatin. External intervention by shRNA-mediated depletion gives rise to 
enhanced resistance to both drugs. The corresponding half-maximal inhibitory concentration (IC50) values are also shown. C. Gel analysis 
comparing the SLFN11 protein immunoprecipitates obtained in NCI-H23 cells from the shRNA scramble cells with the SLFN11-shRNA-
depleted cells, which reveals the marked reduction of a band, which was isolated for further characterization. D. Mass spectrometry (MS) 
analysis of diferential immunoprecipitates for SLFN11 interactors. The MS/MS fragmentation ions of the last peptide are shown in blue and 
red corresponding respectively to y and b ions. E. Coimmunoprecipitation experiments confirmed the interaction of SLFN11 and DHX9. 
Immunoprecipitation and western blot were performed using anti-SLFN11 and anti-DHX9 antibodies. Normal mouse IgG was used as a 
negative control. F. Examples of multi-color immunofluorescence images show colocalization of the SLFN11 (red labeling) and DHX9 
(green labeling) proteins in the nucleus of NCI-H23 cells.
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Table 2: Clinical features of ovarian cancer cohort
N = 41
SLFN11 Methylation Status (U/M)
N % Unmethylated (U) Methylated (M) OR  
(95% CI)
P*
N % N %
Age
<50 5 12% 2 40% 3 60% 1 (reference) -
>50 21 51% 9 43% 12 57% 1.33 (0.16 - 11.3) n.s
Unknown 15 37% 14 93% 1 7% - -
Stage
I 5 12% 4 80% 1 20% 1 (reference) -
II 3 7% 3 100% 0 0% 0.50 (0.25 - 1.01) n.s
III 26 64% 14 54% 12 46% 0.88 (0.72 - 1.08) n.s
IV 7 17% 4 57% 3 43% 0.74 (0.33 - 1.67) n.s
Histology type
Papillary serous 41 100% 25 61% 16 39% - -
Chemotherapy 
schedule
Platinum-based 
schedule 15 37% 14 93% 1 7%
1 
(reference) -
Carboplatin + 
Taxol 26 63% 11 42% 15 58%
0.47 (0.30 - 
0.74) 0.002
Relapse / 
Progression
No 12 29% 10 83% 2 17% 1 (reference) -
Yes 28 68% 15 54% 13 46% 2.79 (0.74 - 10.5) n.s
Unknown 1 3% 0 0% 1 100% - -
Survival
Alive 12 30% 7 58% 5 42% 1 (reference) -
Exitus 29 70% 18 62% 11 38% 1.05 (0.69 - 1.58) n.s
*P-value was assessed according Chi-Square test; p < 0.05 as statistical significant.
SLFN11 methylation status is shown along to the different clinical features of patients.
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using the 450K microarray from illumina, and we have 
related the obtained DNA methylation patterns with 
the available data of cisplatin and carboplatin response 
from the Developmental Therapeutics Program of the 
NCI (http://dtp.nci.nih.gov/). Using this approach we 
have been able to identify SLFN11 CpG promoter island 
hypermethylation as a predictive biomarker of platinum 
resistance.
SLFN11 expression has been previously related 
with cells sensitivity to several DNA damage drugs as 
topotecan, cisplatin and irinotecan [18, 24, 25]. SLFN11 
belongs to the Schlafen protein family, which has been 
implicated in the regulation of important biological 
functions, such as control of cell proliferation and 
induction of immune responses [26], regulation of viral 
replication [20], and, for cancer, in sensitizing cancer 
cells to DNA damaging agents [18, 24, 25]. The SLNF11 
C-terminal is constituted by a DNA/RNA helicase-like 
motif that has not been functionally characterized yet. 
This kind of motif has been described to participate in 
essentials roles of the DNA damage cell response [27]. 
Previous proteomic studies pointed SLFN11 as a putative 
interactor of several key proteins of the DNA damage 
cell response system, such as replication proteins RPA1, 
RPA2 and RPA3 or BRCA1-Associeted Ring Domain 
protein (BARD1) [28, 29]. Herein, our mass spectrometry 
and co-immunoprecipitation analyses indicate that 
the BRCA1-interactor DHX9 as a partner of SLFN11. 
DHX9 is a member of the DEAH-containing family of 
RNA helicases with an enzyme activity that catalyzes the 
ATP-dependent unwinding of double-stranded RNA and 
DNA-RNA complexes [30, 31]. Most importantly, DHX9 
Figure 4: SLFN11 CpG island hypermethylation is an independent factor that is prognostic of poor clinical outcome in 
ovarian and non-small cell lung cancer patients treated with platinum-derived drugs. A. Kaplan-Meier analysis of overall 
survival (OS) and progression-free survival (PFS) in the ovarian cancer clinical cohort with respect to SLFN11 methylation status. The 
statistical significance of the log-rank test is shown. Results of the univariate Cox regression analysis are represented by the hazard ratio 
(HR) and 95% confidence interval (95% CI). The number of cases (n) and the mean time to progression/survival in years (y) is indicated for 
each group. B. Forest plot of multivariate Cox regression, taking into account different clinical features of the validation cohort. Parameters 
with an associated value of p < 0.05 were considered as independent prognostic factors. HR associated with PFS and OS in the ovarian 
cancer cohort. C. Kaplan-Meier analysis of PFS among the non-small cell lung cancer clinical cohort with respect to SLFN11 methylation 
status. The significance of the log-rank test is shown. Results of the univariate Cox regression analysis are represented by the HR and 
95% CI. The number of cases (n) and the mean time to progression/survival in years (y) are indicated for each group. D. Forest plot of 
multivariate Cox regression analysis, taking into account a range of clinical features of the validation cohort. Parameters with an associated 
value of p < 0.05 were considered to be independent prognostic factors. HR associated with PFS in the non-small cell lung cancer cohort.
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has been implicated in genome maintenance processes 
[21, 22]. DHX9 has several interacting partners that are 
directly involved in DNA repair, the most prominent 
being the tumor suppressor BRCA1 [32]. Interestingly, 
epigenetic defects in BRCA1 have been associated 
with increased sensitivity to platinum-derived drugs in 
human cancer [8–10], whilst an impairment of at least 
one BRCA1-interactor protein (SRBC) has been related 
to increased resistance to these compounds [13]. Thus, 
it is reasonable to speculate that SLFN11 epigenetic 
silencing compromises the correct partnership of DHX9 
and BRCA1, and then it alters the correct function of 
the DNA damage response system, causing a shift in 
the platinum-associated chemosensitivity of the affected 
cancer cells.
Finally, in our study we also show that this 
epigenetic molecular alteration can be used as a response 
predictive biomarker to platinum-based therapy in ovarian 
and lung human cancer. Since all tumor samples in our 
studies were collected before chemotherapy we presume 
that the observed hypermethylation of SLFN11 in the 
analyzed tumors confers a growth advantage in these cells 
and it is also a biomarker of primary resistance to the 
mentioned drugs. Future studies on tumor samples before 
Table 3: Clinical features of non-small cell lung cancer adenocarcinoma cohort
N = 22
SLFN11 Methylation Status (U/M)
N % Unmethylated (U) Methylated (M) OR (95% CI) P*
N % N %
Gender
Male 10 45% 8 80% 2 20% 1 (reference) -
Female 12 55% 11 92% 1 8% 0.36 (0.03 – 4.74) n.s
Age
<50 2 9% 2 100% 0 0% 1 (reference) -
>50 20 91% 17 85% 3 15% 0.89 (0.77 – 1.04) n.s
Stage
I 6 27% 5 83% 1 17% 1 (reference) -
II 7 32% 5 71% 2 29% 1.50 (0.27 – 8.34) n.s
III 9 41% 9 100% 0 0% 0.35 (0.17 – 0.72) n.s
IV 0 0% - - - - - -
Smoking-status
No 5 23% 4 80% 1 20% 1 (reference) -
Former 12 54% 11 92% 1 8% 0.53 (0.11 – 2.69) n.s
Yes 5 23% 4 80% 1 20% 1.00 (0.21 – 4.71) n.s
Treatment schedule
RT plus Platinum-
based CT 8 36% 6 75% 2 25% 1 (reference) -
Platinum plus 
Taxane 5 23% 4 80% 1 20% 0.90 (0.35 – 2.32) n.s
Platinum-based CT 9 41% 9 100% 0 0% 0.40 (0.21 - 0.74) n.s
Relapse
No 4 21% 4 100% 0 0% 1 (reference) -
Yes 18 79% 15 83% 3 17% 0.79 (0.63 - 1.01) n.s
* P-value was assessed according Chi-Square test; p < 0.05 as statistical significant.
Abbreviations: RT = Radiotherapy; CT = Chemotherapy; n.s = not significant
SLFN11 methylation status is shown along to the different clinical features of patients.
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and after treatment should be performed to determine 
whether promote CpG island hypermethylation of 
SLFN11 could be a subject of cellular selection generating 
secondary resistance and, if so, whether it could be 
used as a biomarker for the selection of the most useful 
chemotherapy regimen.
MATERIALS AND METHODS
Human cancer cells and tissues
All cell lines were obtained from the American 
Type Culture Collection (Manassas, VA). All cell lines 
were cultured at 37°C in an atmosphere of 5% (v/v) 
carbon dioxide. HCT-116, HCT15, MCF-7, MDA-
MB-231 and 293T cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) while OVCAR-8, 
H23, DU145 and U251 were cultured in Roswell Park 
Memorial Institute medium (RPMI1640). The medium 
was always supplemented with 10% (w/v) fetal bovine 
serum, 100U penicillin, and 100ug/L streptomycin 
(Invitrogen, Carlsbad, CA). Cells were authenticated by 
STR profiling and tested for the absence of mycoplasma. 
Primary ovarian and non-small cell lung cancer samples 
were obtained from the Hospital de la Santa Ceu i Sant 
Pau and the Cancer Epigenetics and Biology Program 
Biobanks. Progression free survival (PFS) and overall 
survival (OS) was determined by using Kaplan-Meier plots 
and Log-Rank test. Statistical analysis was performed by 
using SPSS for Windows and p-values under 0.05 were 
considered statistic significant.
DNA methylation arrays
Whole-genome DNA methylation was analyzed 
in the sixty cell lines of NCI60 panel using the 
Illumina Infinium HumanMethylation450Beadchips. 
DNA was extracted from cell lines and tissues by 
the phenol:chloroform method. All DNA samples 
were assessed for integrity, quantity and purity by 
electrophoresis in a 1.3% agarose gel, picogreen 
quantification, and nanodrop measurement. All samples 
were randomly distributed into 96-well plates. Bisulfite 
conversion of 500 ng of genomic DNA was performed 
using an EZ DNA methylation kit (Zymo Research) 
following the manufacturer’s instructions. 200 ng of 
bisulfite converted DNA were used for hybridization 
on the HumanMethylation450 BeadChip (Illumina). 
Briefly, samples were whole-genome amplified followed 
by enzymatic end-point fragmentation, precipitation 
and resuspension. The resuspended samples were 
hybridized onto the beadchip for 16 h at 48°C and 
washed. Single nucleotide extension with labeled 
dideoxy-nucleotides was performed and repeated 
rounds of staining were carried out with a combination 
of labeled antibodies differentiating between biotin and 
DNP. DNP and biotin staining, hybridization, target 
removal, extension, bisulfite conversion G/T mismatch, 
negative and non-polymorphic control probe intensities 
were inspected as recommended by Illumina. Raw 
fluorescence intensity values were normalized with 
Illumina Genome Studio software (V2011.1) using 
“control normalization” with background correction. 
Normalized intensities were then used to calculate DNA 
methylation levels (beta values). Likewise, data points 
with statistically low power (as reported by detection 
values of p > 0.01) were designated as NA and excluded 
from the analysis. Genotyping probes present on the 
chip as well as DNA methylation probes overlapping 
with known single-nucleotide polymorphisms (SNPs) 
were also removed. Probes were considered to be in a 
promoter CpG island if they were located within a CpG 
island (UCSC database) and less than 1,500 bp away 
from a transcription start site.
Bisulfite sequencing
Genomic DNA was converted using an EZ DNA 
Methylation Gold kit (Zymo Research, Orange, CA, 
USA). A specific region of the promoter island was 
amplified by PCR and cloned in competent bacteria. A 
minimum of eight single clones were interrogated for each 
sample and the methylation frequency was calculated in 
each case.
Expression analysis
For qRT–PCR experiments, total RNA was 
extracted using Trizol® reagent and retrotranscribed using 
the ThermoScript™ RT–PCR System (Invitrogen). The 
reaction was carried out following the methods for use 
of SYBR Green (Applied Biosystems), and HPRT were 
used as housekeeping gene to enable normalization. 
Reactivation treatments with the demethylating agent 
5-aza-2′-deoxycytidine (AZA; Sigma) were performed at 
1 μM for 72 h. For immunoblotting assays, total protein 
was extracted using RIPA (50 mM Tris pH 7.5, 150 mM 
NaCl, 1 mM EDTA and EGTA, 1% NP40, 0.5% of sodium 
deoxycholate, 0.1% of SDS, and protease and phosphatase 
inhibitors from Roche), and specific antibodies against 
target proteins are listed in the enclosed table.
Short hairpin interference and ectopic 
expression assays
Six different short hairpin RNAs (shRNAs) were 
designed over the SLFN11 mRNA to target ovarian and 
lung SLFN11-expressing cells. A shRNA against the 
MSS2 yeast protein (not present in mammals) was used 
as scrambled. All annealed shRNA oligos were ligated 
into pLVX-shRNA2 plasmid, purchased from Clontech, 
using BamH1 and EcoR1 restriction sites. 10 μg of each 
shRNA-encoding plasmid were mixed with 7.5 μg of ps-
PAX2 and 2.5 μg of PMD2.G plasmid in 1 ml JetPRIME 
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buffer and 50ul of JetPRIME (Polyplus-transfection 
S.A., Illkirch, France). After 10 min of RT incubation, 
the transfection mix was added drop-wise to a 10 cm 
dish containing 10 ml of DMEM and 293T cells at 80% 
confluence. After 48 h, viral supernatant was recovered, 
0.45-μm filtered and added to six-well plates containing 
the host cells at 80% confluence. After 48–72 h, cells were 
checked for infection efficiency. For ectopic expression 
assays, normal colon RNA was retrotrascribed and used 
to amplify SLFN11 transcript. Specific adapter primers 
were used to add restrition sites for NotI and XhoI to 5′ 
and 3′ ends of SLFN11 amplification. PCR product and 
pcDNA4/TO expresion vector were digested with fast 
digest XhoI and NotI restriction enzymes (New England) 
and ligated by using T4 enzyme. Competent bacteria were 
transformed with the pcDNA4/TO-SLFN11 vector, grown 
and processed by maxiprep technique. SLFN11 total 
sequence carried in the obtained vector was verified by 
sequencing PCR. HCT-15 and MCF-7 cells in exponential 
growth were electroporated to introduce pcDNA4/TO 
empty vector or pcDNA4/TO carrying SLFN11 cds.
Mass spectrometry analysis
1 mg of nuclear protein extract was recovered 
in 1 ml of RIPA (50 mM Tris pH 7.5, 150 mM NaCl, 
1 mM EDTA and EGTA, 1% NP40, 0.5% of sodium 
deoxycholate, 0.1% of SDS, and protease and phosphatase 
inhibitors from Roche) and putted on ice. After cleaning 
the membrane residues, overnight pre-cleaning was done 
with magnetic beads (Dynabeads® M-280 Sheep Anti-
Mouse IgG, Invitrogen) at 4°C. 10 μg of anti-SLFN11 
antibody from Santacruz (sc-374339) was incubated with 
30 μl of magnetic beads overnight at 4°C in 500ul of PBS. 
After that, beads were removed from the protein solution 
and magnetic beads with antibody were recovered. Beads 
were then cleaned three times with mild wash buffer (PBS 
plus 0.1% of NP40). Target proteins were eluted using 
Laemmli buffer at 90°C for 10 min and eluted proteins 
were separated from beads. Samples were loaded and 
run on a 7.5% polyacrylamide gel. Bands were identified 
staining the gel with silver overnight with Silver Quest 
kit (Invitrogen), following the manufacturers protocol. 
Single bands were excised and sent to the proteomics 
service of IDIBELL (Spain). Mass spectrometry was 
performed in a NanoAcquity (Waters) HPLC coupled 
to an LTQ OrbitrapVelos mass spectrometer (Thermo 
Scientific). Data analysis was carried out in the LTQ 
OrbitrapVelos. Peptide masses were measured in the 
Orbitrap at a resolution of 60,000 (m/z: 300 - 1700). The 
ten most abundant peptides (minimum intensity of 500 
counts) were selected from each MS scan and fragmented 
using CID (38% normalized collision energy) in the linear 
ion trap with helium as the collision gas. All results were 
filtered so only proteins identified with high confidence 
peptides (FDR ≤ 0.01) and with at least two peptides were 
included. Finally, results were filtered by Homo sapiens.
Mass spectrometry validation
For coimmunoprecipitation (CoIP), H23 wild type 
cells were grown at 70% confluence. Nuclear extract was 
prepared with RIPA. Samples were pre-cleared using 
Dynabeads® M-280 Sheep Anti-Mouse IgG (Invitrogen), 
overnight at 4°C in rotation. Antibodies against SLFN11 
(sc-374339, santacruz) and against RHA (sc-137198, 
santacruz) were pre-incubated with beads for two hours at 
4°C in rotation. Samples were cleared of beads, and beads 
with the antibodies attached were recovered. Samples 
were incubated with their respective antibodies at 4°C in 
rotation for 2–4 h. After that, beads were washed three 
times with mild wash buffer (PBS plus 0.1% of NP40). 
Target proteins were then eluted using Laemmli buffer 
at 90°C for 10 min and elution proteins were separated 
from beads. To avoid cross-reactivity and unspecific band 
detection, mouse TrueBlot HRP secondary antibody was 
used. As a CoIP negative control we used normal mouse 
Ig from Millipore (12–371) or Anti-Nucleolin (sc-8031, 
Santacruz).
Colocalization assay
For colocalization analysis, the cells were 
cultured directly on polilysinated coverslips and fixed 
with 4% paraformaldehyde for 10 minutes. Cells were 
permeabilized with 0.1% Triton X-100 for 10 minutes 
and blocked with 2% blocking reagent (Roche) for one 
hour. Immunistaining with SLFN11 (1:300) (sc-136890, 
Santacruz) and RHA (1:500) (sc-137198, santacruz) 
was performed for 16 h at 4°C. Anti-mouse Alexa488 
was used as secondary antibody for RHA detection and 
Anti-goat Alexa555 for detection of SLFN11. Multi-color 
immunofluorescence images were capture and the images 
obtained analyzed with the plugin Intensity Correlation 
Analysis (Image J) to calculate the Manders´R overlap 
colocalization coefficient.
Cell viability assays
Cells were seeded in either 96-well microplates 
at ~15% confluence in medium with 10% FBS and 
penicillin/streptomycin. The optimal cell number for each 
was determined to ensure that each one was in growth 
phase at the end of the assay. After overnight incubation, 
cells were treated with 5–8 concentrations of cisplatin 
1mg/ml (Pfizer) or carboplatin 10mg/ml (Teva) and then 
returned to the incubator for assay after 72 h. Cell viability 
was determined by the 3-(4, 5-dimethy-2-thiazolyl)-2, 
5-diphenyl-2H-tetrazolium bromide (MTT) assay. MTT 
was added at final concentration of 0.1%. After 3 hours of 
incubation (37°C; 5% carbon dioxide), the MTT metabolic 
product formazan was dissolved in dimethyl sulfoxide 
(DMSO), and absorbance was measured at 570nm. Prism 
Software (La Jolla, CA) was used to calculate the drug 
half-maximum inhibitory concentration (IC50).
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